Amgen Engages with U.S. Government for Price Reduction
Amgen (NASDAQ: AMGN), a leader in biotechnology, is taking a vital step to bring down medicine prices for American patients while emphasizing its ongoing dedication to innovation in the pharmaceutical sector. The company aims to align its efforts with recent government initiatives to ensure patient access to necessary medications.
Commitment to Innovation and Manufacturing
The initiative highlights Amgen's commitment to investing in both innovation and U.S. manufacturing practices. By working closely with the U.S. government, particularly in response to recent requests from the Administration regarding drug pricing, Amgen is poised to make a meaningful impact. Robert A. Bradway, Amgen's CEO, states that the U.S. has long been at the forefront of biopharmaceutical innovation and that continued collaboration with government entities is crucial for nurturing this progress.
Expansion of Direct-to-Patient Programs
Amgen plans to broaden its direct-to-patient program, AmgenNow™, to include medicines such as Aimovig (erenumab-aooe) and Amjevita (adalimumab-atto), which will be made available at significantly reduced prices. With monthly costs set at $299, these prices are nearly 60% to 80% lower than current list prices. In addition, the program is open to all patients, including those uninsured or those who choose to utilize out-of-pocket payment options.
Investments in U.S. Manufacturing
Since 2018, Amgen has committed over $40 billion to enhance its manufacturing capabilities and research efforts within the United States. This ongoing investment strategy has been facilitated by favorable tax legislation and is further supported by the recent One Big Beautiful Bill Act of 2025. The company is also executing plans to invest an additional $2.5 billion in capital projects across the U.S., including major manufacturing expansions in Ohio and North Carolina.
Recognition and Achievements
In a demonstration of its commitment to innovation and social responsibility, Amgen has received accolades for its efforts. Notably, the company was recognized as one of the "World's Most Innovative Companies" by Fast Company and listed among "America's Best Large Employers" by Forbes. These honors reflect its dedication to creating a positive impact in the healthcare domain.
Future Prospects
As Amgen continues to evolve and innovate, its focus remains on creating a pipeline of promising medications that address severe health conditions. The future looks bright as they plan to enhance their offerings and expand access to affordable medicines. The company's participation in various innovation collaborations further solidifies its role in advancing healthcare solutions.
Frequently Asked Questions
What initiative has Amgen announced regarding medicine pricing?
Amgen is collaborating with the U.S. government to reduce the cost of medicines for American patients through expanded programs and initiatives.
How much has Amgen invested in U.S. manufacturing and R&D since 2018?
Amgen has invested over $40 billion in manufacturing and research and development to enhance its capabilities in the U.S.
What new medicines will be offered at reduced prices?
Amgen will offer Aimovig and Amjevita at monthly prices of $299, which are significantly lower than current list prices.
What recognitions has Amgen received for its innovation?
Amgen has been recognized as one of the "World's Most Innovative Companies" and among "America's Best Large Employers," highlighting its significant contributions to healthcare.
How does Amgen support patients without insurance?
Amgen's direct-to-patient program is open to all patients, including those who are uninsured or prefer to pay out of pocket for their medications.
